HIV / AIDS - Pipeline Review, H1 2012

HIV / AIDS – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'HIV / AIDS - Pipeline Review, H1 2012', provides an overview of the HIV / AIDS therapeutic pipeline. This report provides information on the therapeutic development for HIV / AIDS, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV / AIDS. 'HIV / AIDS - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for HIV / AIDS.
- A review of the HIV / AIDS products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the HIV / AIDS pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for HIV / AIDS.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding HIV / AIDS pipeline depth and focus of HIV / AIDS therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

HIV / AIDS Therapeutic Products under Development, Key Players in HIV / AIDS Therapeutics, HIV / AIDS Pipeline Overview, HIV / AIDS Pipeline, HIV / AIDS Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
HIV / AIDS Overview
Therapeutics Development
An Overview of Pipeline Products for HIV / AIDS
HIV / AIDS Therapeutics under Development by Companies
HIV / AIDS Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
HIV / AIDS Therapeutics – Products under Development by Companies
HIV / AIDS Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in HIV / AIDS Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
Abbott Laboratories
Vical Incorporated
Shionogi & Co., Ltd.
GlaxoSmithKline plc
Nektar Therapeutics
Antigenics, Inc.
Inovio Biomedical Corporation
Bavarian Nordic A/S
Gilead Sciences, Inc.
VIRxSYS Corporation
Merck & Co., Inc.
United Biomedical, Inc.
Lentigen Corporation
Sangamo BioSciences, Inc.
Generex Biotechnology Corporation
Nanotherapeutics, Inc.
Ambrilia Biopharma Inc.
Biotron Limited
Aphios Corporation
Achillion Pharmaceuticals, Inc.
Esteve Group
InterMune, Inc.
Japan Tobacco Inc.
Sequoia Pharmaceuticals, Inc.
Rottapharm SpA
Indus Biotech Private Limited
Locus Pharmaceuticals, Inc.
Presidio Pharmaceuticals, Inc.
Chimerix, Inc.
Theraclone Sciences, Inc.
Frontier Biotechnologies, Inc.
REPLICor Inc.
Kainos Medicine, Inc.
Viral Genetics, Inc.
Concert Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc.
Tibotec Pharmaceuticals Ltd.
Kemin Industries, Inc.
Heptares Therapeutics Ltd.
VIRIOM Ltd.
CONRAD
ViiV Healthcare
Vichem Chemie Research Ltd.
ImQuest Life Sciences
Tibotec Therapeutics
HIV / AIDS – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Cobicistat - Drug Profile
1349572 - Drug Profile
Truvada - Drug Profile
JTK-303 - Drug Profile
JTK-303 - Drug Profile
SP-01A - Drug Profile
Ampligen - Drug Profile
VGV-1 - Drug Profile
Quad - Drug Profile
Tenofovir + Emtricitabine + Efavirenz - Drug Profile
Emtricitabine + Tenofovir Disoproxil Fumarate - Drug Profile
Zidovudine + Lamivudine + Nevirapine - Drug Profile
Aluvia - Drug Profile
Aluvia + Raltegravir - Drug Profile
Nevirapine - Drug Profile
Emtricitabine + Tenofovir Disoproxil Fumarate + Lopinavir + Ritonavir + Nevirapine - Drug Profile
Proleukin + Anti-HIV Therapy - Drug Profile
Abacavir + Lamivudine + Zidovudine - Drug Profile
Lamivudine + Zidovudine + Nelfinavir - Drug Profile
Emtricitabine + Tenofovir Disoproxil Fumarate + Ritonavir + Atazanavir - Drug Profile
Emtricitabine + Tenofovir Disoproxil Fumarate + Raltegravir - Drug Profile
Emtricitabine + Tenofovir Disoproxil Fumarate + Darunavir + Ritonavir - Drug Profile
Erythromycin + Nevirapine + Ampicillin Sodium + Metronidazole - Drug Profile
Valacyclovir - Drug Profile
Buprenorphine + Naloxone - Drug Profile
Prednisone - Drug Profile
Raltegravir + Truvada - Drug Profile
Stavudine + Lamivudine + Abacavir - Drug Profile
Emtricitabine + Tenofovir - Drug Profile
Tenofovir - Drug Profile
Stavudine + Lamivudine + Nevirapine - Drug Profile
Abacavir + Lamivudine + Nevirapine - Drug Profile
Zidovudine + Lamivudine + Abacavir - Drug Profile
GPO-VIR S + GPO-VIR Z - Drug Profile
Raltegravir - Drug Profile
GPO-VIR Z - Drug Profile
Truvada + Nevirapine - Drug Profile
Didanosine + Abacavir + Kaletra - Drug Profile
Zidovudine + Lamivudine + Kaletra - Drug Profile
Proleukin + Paracetamol + Ibuprofen + Ondansetron + Codeine Phosphate - Drug Profile
Proleukin + Paracetamol + Ibuprofen + Metoclopramide + Codeine Phosphate - Drug Profile
Isentress + Kaletra - Drug Profile
Stavudine + Lamivudine + Nevirapine - Drug Profile
Stavudine + Lamivudine + Efavirenz - Drug Profile
Abacavir + Lamivudine + Nevirapine - Drug Profile
Abacavir + Lamivudine + Efavirenz - Drug Profile
Zidovudine + Lamivudine + Nevirapine - Drug Profile
Zidovudine + Lamivudine + Efavirenz - Drug Profile
Viramune XR - Drug Profile
Zovirax - Drug Profile
Lopinavir + Ritonavir + Efavirenz - Drug Profile
Zalcitabine - Drug Profile
Lopinavir + Ritonavir + Zidovudine - Drug Profile
Remune - Drug Profile
Indinavir + Ritonavir + Abacavir + Didanosine + Proleukin - Drug Profile
Darunavir + Ritonavir - Drug Profile
Tenofovir Disoproxil Fumarate - Drug Profile
Tenofovir + Emtricitabine + Efavirenz - Drug Profile
Isentress + Celsentri + Prezista + Norvir + Truvada - Drug Profile
Clarithromycin + Ethambutol + Rifabutin - Drug Profile
Clarithromycin + Ethambutol + Clofazimine - Drug Profile
Viramune + Truvada - Drug Profile
Telzir + Norvir + Abacavir + Lamivudine - Drug Profile
Sustiva + Epzicom - Drug Profile
Atazanavir + Ritonavir + Abacavir + Lamivudine - Drug Profile
Lamivudine + Zidovudine + Nelfinavir + Efavirenz - Drug Profile
Nevirapine + Lopinavir + Ritonavir - Drug Profile
Ritonavir + Saquinavir + Efavirenz - Drug Profile
Ziodovudine + Alpha Interferon - Drug Profile
Lopinavir + Ritonavir - Drug Profile
Zidovudine + Lamivudine + Ritonavir + Indinavir 7 - Drug Profile
Enfuvirtide + Raltegravir + Darunavir + Tipranavir + Etravirine + Maraviroc - Drug Profile
Indinavir Sulfate + Lamivudine + Zidovudine - Drug Profile
Abacavir + Lamivudine + Atazanavir + Ritonavir - Drug Profile
Abacavir Sulfate + Didanosine + Efavirenz + Lamivudine + Lopinavir + Nevirapine + Zidovudine - Drug Profile
Levocarnitine + Adefovir dipivoxil - Drug Profile
Lopinavir + Ritonavir + Nucleoside Reverse Transcriptase Inhibitors + PEG-IFNa 2a + Ribavirin - Drug Profile
Nevirapine + Rifampicin + Ethambutol + Isoniazid + Pyrazinamid - Drug Profile
Raltegravir + Maraviroc + Tenofovir + Emtricitabine - Drug Profile
Viread + Aluvia - Drug Profile
Truvada + Nevirapine - Drug Profile
Truvada + Zidovudine - Drug Profile
Truvada - Drug Profile
Abacavir + Lamivudine + Efavirenz - Drug Profile
Darunavir + Ritonavir + Raltegravir - Drug Profile
Atazanavir + Didanosine + Efavirenz + Emtricitabine + Tenofovir Disoproxil Fumarate + Lamivudine + Lopinavir + Ritonavir + Nevirapine + Stavudine + Zidovudine - Drug Profile
Raltegravir + Maraviroc + Emtricitabine + Tenofovir + Lopinavir + Ritonavir - Drug Profile
Lopinavir + Ritonavir - Drug Profile
Darunavir + Ritonavir - Drug Profile
Isentress + Celsentri + Truvada + Kaletra - Drug Profile
Truvada + Raltegravir - Drug Profile
Fuzeon + Truvada + Kaletra - Drug Profile
Abacavir - Drug Profile
Abacavir + Lamivudine + Efavirenz - Drug Profile
Efavirenz - Drug Profile
Etravirine - Drug Profile
Valsartan - Drug Profile
Viread + Epivir + Sustiva - Drug Profile
Zerit + Epivir + Sustiva - Drug Profile
Lopinavir + Ritonavir + Lamivudine + Stavudine - Drug Profile
Efavirenz + Lamivudine + Stavudine - Drug Profile
Efavirenz + Lamivudine + Tenofovir - Drug Profile
Lopinavir + Ritonavir + Lamivudine + Tenofovir Disoproxil Fumarate - Drug Profile
Intelence + Prezista + Ritonavir - Drug Profile
Maraviroc + Antiretroviral Therapy - Drug Profile
Lamivudine + Tenofovir + Atazanavir + Ritonavir - Drug Profile
572-Trii - Drug Profile
Atazanavir Sulphate + Ritonavir - Drug Profile
Hepavax-Gene - Drug Profile
Reyataz + Cobicistat - Drug Profile
Cobicistat + Prezista - Drug Profile
Pentamidine - Drug Profile
RemuneX - Drug Profile
HIV / AIDS Therapeutics – Drug Profile Updates
HIV / AIDS Therapeutics – Discontinued Products
HIV / AIDS Therapeutics - Dormant Products
HIV / AIDS – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for HIV / AIDS, H1 2012
Products under Development for HIV / AIDS – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Development by Companies, H1 2012 (Contd..5)
Number of Products under Development by Companies, H1 2012 (Contd..6)
Number of Products under Development by Companies, H1 2012 (Contd..7)
Number of Products under Development by Companies, H1 2012 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Development by Companies, H1 2012 (Contd..6)
Products under Development by Companies, H1 2012 (Contd..7)
Products under Development by Companies, H1 2012 (Contd..8)
Products under Development by Companies, H1 2012 (Contd..9)
Products under Development by Companies, H1 2012 (Contd..10)
Products under Development by Companies, H1 2012 (Contd..11)
Products under Development by Companies, H1 2012 (Contd..12)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..25)
Bristol-Myers Squibb Company, H1 2012
Johnson & Johnson, H1 2012
Boehringer Ingelheim GmbH, H1 2012
Abbott Laboratories, H1 2012
Vical Incorporated, H1 2012
Shionogi & Co., Ltd., H1 2012
GlaxoSmithKline plc, H1 2012
Nektar Therapeutics, H1 2012
Antigenics, Inc., H1 2012
Inovio Biomedical Corporation, H1 2012
Bavarian Nordic A/S, H1 2012
Gilead Sciences, Inc., H1 2012
VIRxSYS Corporation, H1 2012
Merck & Co., Inc., H1 2012
United Biomedical, Inc., H1 2012
Lentigen Corporation, H1 2012
Sangamo BioSciences, Inc., H1 2012
Generex Biotechnology Corporation, H1 2012
Nanotherapeutics, Inc., H1 2012
Ambrilia Biopharma Inc., H1 2012
Biotron Limited, H1 2012
Aphios Corporation, H1 2012
Achillion Pharmaceuticals, Inc., H1 2012
Esteve Group, H1 2012
InterMune, Inc., H1 2012
Japan Tobacco Inc., H1 2012
Progenics Pharmaceuticals, Inc., H1 2012
Hadasit Medical Research Services & Development Ltd, H1 2012
Avexa Limited, H1 2012
Koronis Pharmaceuticals, Inc., H1 2012
Trimeris, Inc., H1 2012
GeoVax Labs, Inc., H1 2012
Hemispherx Biopharma, Inc., H1 2012
Celldex Therapeutics, Inc., H1 2012
Enzo Biochem, Inc., H1 2012
Ardea Biosciences, Inc., H1 2012
Medivir AB, H1 2012
Bio-Bridge Science, Inc., H1 2012
Benitec Ltd., H1 2012
ReGenX Biosciences, LLC, H1 2012
Mymetics Corporation, H1 2012
NanoViricides, Inc., H1 2012
Nutra Pharma Corporation, H1 2012
Critical Outcome Technologies Inc., H1 2012
Pharmasset, Inc, H1 2012
CytoGenix, Inc., H1 2012
ADVENTRX Pharmaceuticals, H1 2012
Starpharma Holdings Limited, H1 2012
Immuron Limited, H1 2012
Samaritan Pharmaceuticals, Inc., H1 2012
BioAlliance Pharma SA, H1 2012
Eurocine Vaccines AB, H1 2012
Paloma Pharmaceuticals, Inc., H1 2012
Antigen Express, Inc., H1 2012
SCYNEXIS, Inc., H1 2012
Nutri Pharma ASA, H1 2012
Neurotune AG, H1 2012
BioMAS Ltd., H1 2012
Vironova AB, H1 2012
ViroStatics, srl, H1 2012
Argos Therapeutics, Inc., H1 2012
Cytheris SA, H1 2012
Altor BioScience Corporation, H1 2012
Osel Inc., H1 2012
Heat Biologics, Inc., H1 2012
AiCuris GmbH & Co. KG, H1 2012
Viroblock S.A., H1 2012
AlphaVax, Inc., H1 2012
ReProtect, Inc., H1 2012
Sequoia Pharmaceuticals, Inc., H1 2012
Rottapharm SpA, H1 2012
Indus Biotech Private Limited, H1 2012
Locus Pharmaceuticals, Inc., H1 2012
Presidio Pharmaceuticals, Inc., H1 2012
Chimerix, Inc., H1 2012
Theraclone Sciences, Inc., H1 2012
Frontier Biotechnologies, Inc., H1 2012
REPLICor Inc., H1 2012
Kainos Medicine, Inc., H1 2012
Viral Genetics, Inc., H1 2012
Concert Pharmaceuticals, Inc., H1 2012
Myriad Pharmaceuticals, Inc., H1 2012
CytoDyn, Inc., H1 2012
GeneCure LLC, H1 2012
Oncolys BioPharma Inc., H1 2012
Globeimmune, Inc., H1 2012
Etubics Corporation, H1 2012
Immunocore Limited., H1 2012
Canopus BioPharma Incorporated, H1 2012
PepTcell Limited, H1 2012
TVAX Biomedical, LLC, H1 2012
Tobira Therapeutics, Inc., H1 2012
Genetic Immunity, LLC, H1 2012
Virax Holdings Limited, H1 2012
TNI Pharmaceuticals, Inc., H1 2012
Medisyn Technologies, Inc., H1 2012
Pharis Biotec GmbH, H1 2012
Amazon BioTech, H1 2012
Ferring Pharmaceuticals, Inc., H1 2012
Tibotec Pharmaceuticals Ltd., H1 2012
Kemin Industries, Inc., H1 2012
Heptares Therapeutics Ltd., H1 2012
VIRIOM Ltd., H1 2012
CONRAD, H1 2012
ViiV Healthcare, H1 2012
Vichem Chemie Research Ltd., H1 2012
ImQuest Life Sciences, H1 2012
Tibotec Therapeutics, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
HIV / AIDS Therapeutics – Drug Profile Updates
HIV / AIDS Therapeutics – Discontinued Products
HIV / AIDS Therapeutics – Discontinued Products (Contd..1)
HIV / AIDS Therapeutics – Discontinued Products (Contd..2)
HIV / AIDS Therapeutics – Discontinued Products (Contd..3)
HIV / AIDS Therapeutics – Discontinued Products (Contd..4)
HIV / AIDS Therapeutics – Discontinued Products (Contd..5)
HIV / AIDS Therapeutics – Discontinued Products (Contd..6)
HIV / AIDS Therapeutics – Discontinued Products (Contd..7)
HIV / AIDS Therapeutics – Dormant Products
HIV / AIDS Therapeutics – Dormant Products (Contd..1)
HIV / AIDS Therapeutics – Dormant Products (Contd..2)
HIV / AIDS Therapeutics – Dormant Products (Contd..3)
HIV / AIDS Therapeutics – Dormant Products (Contd..4)
HIV / AIDS Therapeutics – Dormant Products (Contd..5)
HIV / AIDS Therapeutics – Dormant Products (Contd..6)
HIV / AIDS Therapeutics – Dormant Products (Contd..7)
HIV / AIDS Therapeutics – Dormant Products (Contd..8)
HIV / AIDS Therapeutics – Dormant Products (Contd..9)
HIV / AIDS Therapeutics – Dormant Products (Contd..10)
HIV / AIDS Therapeutics – Dormant Products (Contd..11)
HIV / AIDS Therapeutics – Dormant Products (Contd..12)
HIV / AIDS Therapeutics – Dormant Products (Contd..13)
HIV / AIDS Therapeutics – Dormant Products (Contd..14)
HIV / AIDS Therapeutics – Dormant Products (Contd..15)
HIV / AIDS Therapeutics – Dormant Products (Contd..16)
HIV / AIDS Therapeutics – Dormant Products (Contd..17)
HIV / AIDS Therapeutics – Dormant Products (Contd..18)
HIV / AIDS Therapeutics – Dormant Products (Contd..19)
HIV / AIDS Therapeutics – Dormant Products (Contd..20)
HIV / AIDS Therapeutics – Dormant Products (Contd..21)
HIV / AIDS Therapeutics – Dormant Products (Contd..22)
HIV / AIDS Therapeutics – Dormant Products (Contd..23)
HIV / AIDS Therapeutics – Dormant Products (Contd..24)
HIV / AIDS Therapeutics – Dormant Products (Contd..25)
HIV / AIDS Therapeutics – Dormant Products (Contd..26)
HIV / AIDS Therapeutics – Dormant Products (Contd..27)
HIV / AIDS Therapeutics – Dormant Products (Contd..28)
HIV / AIDS Therapeutics – Dormant Products (Contd..29)
HIV / AIDS Therapeutics – Dormant Products (Contd..30)
HIV / AIDS Therapeutics – Dormant Products (Contd..31)
HIV / AIDS Therapeutics – Dormant Products (Contd..32)
HIV / AIDS Therapeutics – Dormant Products (Contd..33)
HIV / AIDS Therapeutics – Dormant Products (Contd..34)
HIV / AIDS Therapeutics – Dormant Products (Contd..35)
HIV / AIDS Therapeutics – Dormant Products (Contd..36)
HIV / AIDS Therapeutics – Dormant Products (Contd..37)
HIV / AIDS Therapeutics – Dormant Products (Contd..38)
HIV / AIDS Therapeutics – Dormant Products (Contd..39)
HIV / AIDS Therapeutics – Dormant Products (Contd..40)

List of Figures
Number of Products under Development for HIV / AIDS, H1 2012
Products under Development for HIV / AIDS – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.